Order book strong, capex cut signals caution amid margin pressure
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Order book raised (₹16,260 Cr vs ₹15,000 Cr), cell ramp on track, margins within range. Capex guidance cut 53% from ₹5,100 Cr to ₹2,400 Cr.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong order book ₹16,260 Cr and cell ramp support medium-term growth, but delivered Q2 shows margin compression (OPM 28% vs 29-30% guidance), QoQ PAT decline -2%, and capex cut signals capital constraints. China policy uncertainty and battery profitability unproven.
₹2631.9 Cr
Revenue · +43.3% YoY₹462.4 Cr
Reported PAT · +30.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 revenue ₹2,656 Cr, up 38.2% YoY
OVERSTATEDDelivered ₹2,631.9 Cr, up 43.3% YoY; mgmt claim lower than actual YoY but revenue figure 1% high
PAT ₹462 Cr, up 30.8% YoY
METDelivered ₹462.4 Cr, up 30.8% YoY
Solar EBITDA margin 29.3%, PAT margin 17.9%
METDelivered OPM 28.0%, NPM 17.4%; slightly higher than full-co EBITDA/PAT margins
Order book ₹16,260 Cr, up from ₹15,000 Cr prior
METOrders mentioned; prior guidance was ₹15,000 Cr, so ₹16,260 Cr is raise
7 GW cell line commissioned, 70% utilization by March FY27
METCell line commissioned, trial runs underway, commercial production starting Nov 2026; ramp tracking guidance
QoQ PAT stable/modest growth
MISSDelivered QoQ PAT -2.0%; quarter was flat to slightly down QoQ
Earnings quality
What changed since the last call
Order book up
Upgrade₹16,260 Cr vs ₹15,000 Cr prior call; ₹4,001 Cr new cell/module wins in highly competitive market
Capex cut
DowngradeFY27 revised to ₹2,400 Cr from ₹5,100 Cr plan; bulk of cell/module expansion complete, now marginal leftovers
Transformer margin
DowngradeQ1 margin 22%, Q2 margin 12%; commodity cost increases (steel, copper) impacted, expect normalize to 15% going forward
Ingot-wafer
New10 GW capacity planned by June 2028 (Phase 1: 5 GW by Dec 2027, Phase 2: +5 GW by June 2028); wafer supplier TBD pending China policy
The Q&A
Analysts pressed hard on China policy, margin trends, inventory buildup, and capex priorities. Management acknowledged China uncertainty (policy due Nov 15) but maintained confidence in BOM strategy. Defended inventory as ramp-related, not inventory error. Deferred capex details and forward growth plans pending semiconductor/BESS clarity.
Battery manufacturing localization — Shubham Borade, ICICI Securities
AnsweredBESS operationalization expected Q2 2027. Localizing container manufacturing and fire suppression systems in-house. 7 GW cell line MNRE approval expected by Nov; inspection underway from NISE for ALMM enrolment.
DCR pricing and order mix — Apoorva Bahadar, IIFL Capital
AnsweredDCR pricing INR21-INR22 per watt on average; C&I INR21.5; IPP INR20.5; non-DCR INR12.75-INR13; inventory buildup due to ramp-up and delivery delays, expect normalization by March.
China ALMM policy risk — Sumit Kishore, Axis Capital
PartialChina policy not yet clear; awaiting final announcement Nov 15. Already imported high-tech equipment for Naidupeta cell line, which gives competitive advantage. Most equipment suppliers have SE Asia backup. Hoping for resolution.
Transformer capacity ramp and margins — Kunal Shah, DAM Capital
AnsweredCell line 25-30% CUF in Dec, ramp to 70% by end-March. Transformer 4 GVA already commissioned. Expect 80-90% ramp over 3 years. Normalized transformer margin 15%; Q2 was 12% due to commodity cost increases.
Non-DCR order book and SECI tender — Bharani, Avendus Spark
PartialNo product-by-product breakdown given. SECI tender treated as IPP at ~INR17-18/watt introductory rate to build credentials; not indicative of market pricing. Cells/modules DCR 48%, modules non-DCR 20%, rest DCR business.
U.S. expansion and China policy — Sahil Sheth, Anand Rathi
PartialU.S. and Europe are geographies of interest. Make in America policy is positive. Cell manufacturing in U.S. being finalized with JV partner; 12-18 months timeline. No firm commitment yet.
BESS demand and China component sourcing — Amit, UBS
AnsweredBESS demand currently 50-60 GW annually. Expecting strong growth. 40% localization achievable with cell-to-pack, pack-to-container, and software in-house. No ban on BESS manufacturing components from China.
Order book mix and capex outlook — Amit Bhinde, Axis Capital
AnsweredRetail ~35-40%, C&I and utilities rest. Non-DCR ~25-30% of order book. FY27 capex ~₹2,400 Cr; next two quarters ~₹700 Cr each. Capex for cell/module expansion largely complete.
International geography expansion — Bharani, Avendus Spark (second question)
DodgedU.S. and Europe remain geographies of interest for policy push. Strong policy support for domestic manufacturing. Evaluating opportunities in both markets and internationally.
Cell order book decline explanation — Sahil Sheth, Anand Rathi (second question)
AnsweredCell order book declined as 5.6 GW module line commissioned; we are consuming more cells internally. Prefer to use cells for module consumption, gradually reducing cell sales.
Guidance
FY27 revenue growth mid-to-high 30s% expected (implied from order book execution)
MediumOrder book ₹16,260 Cr supports growth. Cell ramp execution key. Macro headwinds (commodity inflation, shipping) risk.
Solar segment EBITDA margin 29-30%, PAT margin 17.9-18.5% sustainable
MediumQ2 delivered 29.3% EBITDA, 17.9% PAT. Commodity price volatility and DCR mix pressure offset by cell line operating leverage.
Transformer margin normalize to 15% from 12% Q2 (commodity reset assumption)
MediumQ1 was 22%, Q2 12% due to steel/copper increases. Management expects stabilization as commodity cycle eases.
FY27 capex ~₹2,400 Cr (revised down from ₹5,100 Cr announced)
HighBulk of cell/module expansion complete. Next 2 quarters ~₹700 Cr each. Battery/ingot-wafer projects being evaluated for future capex.
Risks the call surfaced
Commodity price volatility
HighTransformer margin fell from 22% (Q1) to 12% (Q2); commodity cost headwinds ongoing. Module BOM inflation impacting realizations.
China export control policy
HighChina government finalizing ALMM (ultra-thin wafer) export policy by Nov 15. Impact on ingot-wafer equipment import timelines and 10 GW capex schedule.
Margin compression from pricing
MediumDCR module pricing range INR21-INR22/watt with aggressive competition. Non-DCR pricing declining. Margin sustainability at risk.
Battery Energy Storage regulatory risk
MediumBESS profitability dependent on government KUSUM 2.0, Surya Ghar 2.0, and BESS scheme announcements. Operating margins TBD. 40% localization requirement achievable but capex-intensive.
Inventory and working capital pressure
MediumInventory buildup ~₹1.5% of sales. Management attributes to ramp-up preparation and shipping congestion. Temporary, expect normalization by Q4.
Management
Score 6/10. Chiranjeev Saluja (MD) confident on strategy but cautious on near-term macro; Vinay Rustagi detailed on pricing, transparent on inventory challenges; deflected on product-by-product margins and forward capex details. Delivered on cell line commissioning (7 GW), transformer capacity (4 GVA), order book ramp (₹16,260 Cr). Capex guidance cut 53% signals slower execution pace. QoQ PAT -2% indicates execution challenges despite strong YoY.
1 · Nov 15, 2026
China policy on ALMM equipment exports; clarity on ingot-wafer sourcing
2 · Dec 2026
7 GW cell line commercial production ramp; 25-30% CUF expected
3 · Mar 2027
Cell line 70% utilization; ingot-wafer plant Phase 1 commissioning Dec 2027
China policy uncertainty and battery profitability unproven.
Informational and educational content only. Not investment advice.